A phase II study of cis-diamminedichloroplatinum (CDDP, 80 mg/m2, every 3 weeks) was performed in patients with non-small cell lung cancer (NSCLC). The overall response rate to CDDP was 14% (6/42). In patients without prior chemotherapy, the response rate was 20% (2/10), and in patients with prior chemotherapy, the response rate was 13% (4/31). The major side effect was gastrointestinal toxicity. It was concluded that CDDP at a dose of 80 mg/m2 every 3 weeks is effective against NSCLC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
response rate
12
phase study
8
study cis-diamminedichloroplatinum
8
patients non-small
8
non-small cell
8
cell lung
8
lung cancer
8
mg/m2 weeks
8
patients prior
8
prior chemotherapy
8
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!